Home >> Oncology/Hematology >> Oncology/Hematology >> Baked Goods >> Technology & Media >>

Hepatic (Liver) Metastasis - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 61 | Code: MRS - 18274

Hepatic (Liver) Metastasis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Hepatic (Liver) Metastasis - Pipeline Review, H1 2015’, provides an overview of the Hepatic (Liver) Metastasis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatic (Liver) Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Metastasis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatic (Liver) Metastasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hepatic (Liver) Metastasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hepatic (Liver) Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatic (Liver) Metastasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatic (Liver) Metastasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatic (Liver) Metastasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hepatic (Liver) Metastasis Overview 7
Therapeutics Development 8
Pipeline Products for Hepatic (Liver) Metastasis - Overview 8
Pipeline Products for Hepatic (Liver) Metastasis - Comparative Analysis 9
Hepatic (Liver) Metastasis - Therapeutics under Development by Companies 10
Hepatic (Liver) Metastasis - Therapeutics under Investigation by Universities/Institutes 11
Hepatic (Liver) Metastasis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Hepatic (Liver) Metastasis - Products under Development by Companies 14
Hepatic (Liver) Metastasis - Products under Investigation by Universities/Institutes 15
Hepatic (Liver) Metastasis - Companies Involved in Therapeutics Development 16
BioCancell Therapeutics, Inc. 16
CytRx Corporation 17
Digna Biotech, S.L. 18
Gradalis Inc. 19
Incuron, LLC 20
Novartis AG 21
Phosplatin Therapeutics LLC 22
Targetome 23
Hepatic (Liver) Metastasis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
Antibodies to Inhibit FRMD4A for Oncology - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
BC-821 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
cancer vaccine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Cell Therapy to Target CEA for Oncology - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cyt-HiPoA - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
DB-02901 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
mepacrine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Monoclonal Antibody Conjugated to Activate p53 for Hepatic Metastasis - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pasireotide - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
PT-112 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Recombinant Protein to Antagonize IGF-1R for Liver Metastasis and Breast Cancer - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
TGM-002 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
TGM-003 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Hepatic (Liver) Metastasis - Recent Pipeline Updates 50
Hepatic (Liver) Metastasis - Dormant Projects 56
Hepatic (Liver) Metastasis - Discontinued Products 57
Hepatic (Liver) Metastasis - Product Development Milestones 58
Featured News & Press Releases 58
Apr 16, 2014: Cleveland BioLabs Announces the Successful Completion of a Phase 1 Study of CBL0102 58
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables
Number of Products under Development for Hepatic (Liver) Metastasis, H1 2015 8
Number of Products under Development for Hepatic (Liver) Metastasis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Hepatic (Liver) Metastasis - Pipeline by BioCancell Therapeutics, Inc., H1 2015 16
Hepatic (Liver) Metastasis - Pipeline by CytRx Corporation, H1 2015 17
Hepatic (Liver) Metastasis - Pipeline by Digna Biotech, S.L., H1 2015 18
Hepatic (Liver) Metastasis - Pipeline by Gradalis Inc., H1 2015 19
Hepatic (Liver) Metastasis - Pipeline by Incuron, LLC, H1 2015 20
Hepatic (Liver) Metastasis - Pipeline by Novartis AG, H1 2015 21
Hepatic (Liver) Metastasis - Pipeline by Phosplatin Therapeutics LLC, H1 2015 22
Hepatic (Liver) Metastasis - Pipeline by Targetome, H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Hepatic (Liver) Metastasis Therapeutics - Recent Pipeline Updates, H1 2015 50
Hepatic (Liver) Metastasis - Dormant Projects, H1 2015 56
Hepatic (Liver) Metastasis - Discontinued Products, H1 2015 57

List of Figures
Number of Products under Development for Hepatic (Liver) Metastasis, H1 2015 8
Number of Products under Development for Hepatic (Liver) Metastasis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Top 10 Targets, H1 2015 25
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Top 10 Routes of Administration, H1 2015 29
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30
Number of Products by Top 10 Molecule Types, H1 2015 31
Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing